Robert Garnick joins Peregrine
This article was originally published in SRA
Executive Summary
Peregrine Pharmaceuticals in the US has appointed Robert Garnick head of regulatory affairs. Dr Garnick will be responsible for overseeing Peregrine's interactions with the US Food and Drug Administration and global regulatory agencies; he will also lead the development of regulatory strategies for advancing the company's monoclonal antibody-based treatments for cancer and infectious diseases.
You may also be interested in...
Bluebird Expects Three Filings In 2020, But US Zynteglo Submission Pushed Back
A BLA filing for Zynteglo in beta-thalassemia is expected in the second half of 2020 instead of the first half, but the first commercial patient in the EU will be treated in the first half of this year.
Balancing Act: China Approves Antiviral For Coronavirus While Promoting Traditional Medicines
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
Pataday Switch Appoval Dilates Eye Drop Category As Alcon's OTC Sales Driver
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: